# Liraglutide Injection: FDA shortage status

> FDA source status only. Nationwide status is not local pharmacy inventory. This page does not provide medical, treatment, substitution, or dosing advice.

- Derived status: current
- Source statuses: Current, To Be Discontinued
- FDA package records: 10
- Latest FDA row update: 08/17/2026
- Retrieved: 2026-08-22T15:54:11+00:00

## FDA package and manufacturer records

- Hikma Pharmaceuticals USA, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) — FDA availability: Available — updated: 08/13/2026
- Hikma Pharmaceuticals USA, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) — FDA availability: Available — updated: 08/13/2026
- Meitheal Pharmaceuticals, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) — FDA availability: Available — updated: 06/01/2026
- Meitheal Pharmaceuticals, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) — FDA availability: Limited Availability — updated: 06/01/2026
- Novo Nordisk, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) — FDA availability: Available — updated: 08/17/2026
- Novo Nordisk, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) — FDA availability: Available — updated: 08/17/2026
- Novo Nordisk, Inc. — Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) — FDA availability: Available — updated: 08/17/2026
- Novo Nordisk, Inc. — Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) — FDA availability: Limited Availability — updated: 08/17/2026
- Novo Nordisk, Inc. — Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) — FDA availability: Limited Availability — updated: 08/17/2026
- Teva Pharmaceuticals USA, Inc. — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) — FDA availability: Not stated — updated: 05/14/2026

## Sources and formats

- [FDA openFDA source](https://api.fda.gov/drug/shortages.json)
- [Canonical HTML](https://citefacts.com/shortages/liraglutide-injection)
- [JSON record](https://citefacts.com/shortages/liraglutide-injection.json)